FindMyKOL
Clinical trialNCT06855108RecruitingPhase 3Interventional

Caffeine for Hypoxic Ischemic Encephalopathy

SponsorNICHD Global Network for Women's and Children's HealthEnrollment830Hypoxic Ischemic Encephalopathy (HIE)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early \[\<1 hour\] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg/kg dose of oral caffeine followed by two additional 10 mg/kg doses at 24-hour intervals or placebo of the same regimen (three total doses). The goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bangladesh
  • Icddr,b

    Saidpur, Bangladesh

    Rashidul Haque, MDSK Masum BillahWilliam A Petri, MD
    Recruiting
Democratic Republic of the Congo
  • Kinshasa School of Public Health

    Kinshasa, Democratic Republic of the Congo

    Adrien Lokangaka, MD, MPHAntoinette Tshefu, MD, PhD, MPHJackie Patterson, MD, MPHKeia Sanderson, MD, MSCRMelissa Bauserman, MD, MPH
    Not, yet, recruiting
Guatemala
  • Institute of Nutrition of Central America and Panama (incap)

    Chimaltenango, Guatemala

    Edwin J Asturias, MDManolo Mazariegos, MD, MPHNancy F Krebs, MD
    Recruiting
India
  • Kle University'S J N Medical College

    Belagavi, India

    Richard J Derman, MD, MPHShivaprasad S Goudar, MD, MHPE
    Not, yet, recruiting
  • Lata Medical Research Foundation

    Nagpur, India

    Archana Patel, MD, DNB, MSCE, PhD
    Not, yet, recruiting
Pakistan
  • Aga Khan University

    Karachi, Pakistan

    Blair Wylie, MDRobert L Goldenberg, MDSarah Saleem, MD
    Not, yet, recruiting
Zambia
  • University Teaching Hospital

    Lusaka, Zambia

    Elwyn Chomba, MBChB, DCH, MRCPWally A. Carlo, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CaffeinePlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Apr 2026
Primary completion
31 Dec 2029
Completion
31 Jul 2030
Last update posted
24 Jun 2026
Registered enrollment
830
Registry id
NCT06855108

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.